EU Finds Lundbeck Pay-For-Delay Deals Blocked Generics

Law360, New York (July 25, 2012, 1:57 PM EDT) -- The European Commission accused Danish drugmaker H. Lundbeck A/S and others on Wednesday of violating EU antitrust rules by inking so-called pay-for-delay deals with generic competitors to keep cheaper versions of blockbuster antidepressant citalopram off the market.

The antitrust body sent statements of objections to Lundbeck and several other drugmakers, including Merck KGaA, Ranbaxy Laboratories Ltd. and Xellia Pharmaceuticals AS. In the statements, the commission found that Lundbeck entered into agreements with rivals to halt the production of generics after Lundbeck's patents covering the drug had...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.